VIRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Viracta Therapeutics has the Momentum Rank of 8.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Viracta Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Momentum Rank distribution charts can be found below:
* The bar in red indicates where Viracta Therapeutics's Momentum Rank falls into.
Thank you for viewing the detailed overview of Viracta Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark Rothera | director, officer: President and CEO | C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
Daniel R. Chevallard | officer: Chief Executive Officer | C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
Darrel P. Cohen | officer: Chief Medical Officer | C/O VIRACTA THERAPEUTICS, INC., 2533 S. COAST HWY 101, SUITE 210, CARDIFF CA 92007 |
Lisa Rojkjaer | officer: Chief Medical Officer | C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007 |
Ivor Royston | director, officer: CEO & President | 4401 WILSHIRE BLVD., SUITE 200, LOS ANGELES CA 90010 |
Jane Chung | director | C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080 |
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Flavia Borellini | director | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Barry J. Simon | director | 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007 |
Stephen Rubino | director | C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007 |
Gur Roshwalb | director, 10 percent owner | C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018 |
Roger Pomerantz | director | 711 HARVEST HILL ROAD, CHALFONT PA 18914 |
Michael Huang | director | C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801 |
Amoon Growth Fund Limited Partnership | 10 percent owner | 34 YERUSHALAYIM RD., RAANANA L3 4350110 |
Thomas E Darcy | director | C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121 |
From GuruFocus
By Value_Insider Value_Insider • 11-02-2022
By Marketwired • 08-14-2023
By sperokesalga sperokesalga • 05-11-2023
By GlobeNewswire GlobeNewswire • 01-08-2023
By sperokesalga sperokesalga • 05-31-2023
By Marketwired • 08-08-2023
By Value_Insider Value_Insider • 12-01-2022
By Marketwired • 10-04-2023
By sperokesalga sperokesalga • 05-02-2023
By GlobeNewswire GlobeNewswire • 11-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.